T cell receptor alpha joining 35 (non-functional)Genealiases: []
Q-omics provides the consensus-scored TRAJ35 profile across patient tissues and cancer cell-line models. TRAJ35 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRAJ35 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, TRAJ35 RNA expression shows 11,048 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where TRAJ35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ35 survival associations across molecular data types. TRAJ35 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ35 RNA expression–survival associations across cancer types. High TRAJ35 expression shows unfavorable associations in ACC, UCS, OV and LGG, but favorable associations in ESCA and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRAJ35 RNA expression.
This table summarizes TRAJ35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ35 shows lower tumor expression in KIRP, KIRC, KICH and COAD and higher tumor expression in BRCA and STAD. The KIRP box plot shows higher TRAJ35 RNA expression in normal versus tumor tissue (log2 FC = −1.125, t-test p < 0.001).
This table shows molecular features associated with TRAJ35 in patient tissues and cancer cell lines. In patient samples, TRAJ35 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
